An exciting moment for our team today as we celebrated becoming a public company by ringing the #OpeningBell at Nasdaq! This moment marks an important new chapter in our journey, reinforcing our commitment to developing therapies that could make a meaningful difference in the lives of those living with #cancer. We extend our gratitude to our hard working, dedicated and talented team whose drive and passion made this achievement possible. 🎉 #IPO
Bicara Therapeutics
Biotechnology Research
Boston, Massachusetts 8,624 followers
Dual-action antibodies bringing together the precision of targeted therapies and the power of tumor modulators
About us
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.
- Website
-
http://www.bicara.com
External link for Bicara Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Immunotherapy, Targeted Oncology, and Drug Discovery
Locations
-
Primary
Boston, Massachusetts, US
Employees at Bicara Therapeutics
Updates
-
Bicara Chief Executive Officer Claire Mazumdar will present at the Stifel 2024 Healthcare Conference in New York, NY. View the details and access the live webcasts and replays on our website here: https://lnkd.in/gfy8e4NR
-
This morning, we announced our third quarter 2024 financial results and business update, highlighting the strong development progress we have made with ficerafusp alfa and the successful completion of our upsized initial public offering. For more details, read the full press release here: https://lnkd.in/gkPiFksa
-
Bicara Therapeutics reposted this
🔬 Cancer doesn’t wait. Neither does Bicara Therapeutics. 👩⚕️ $BCAX’s mission as a clinical stage biotherapeutic company is clear: to turn groundbreaking discoveries into real, life-altering new cancer therapies. 🎉 Honored to be your exchange partner, congrats on becoming #NasdaqListed!
-
Bicara Therapeutics reposted this
🔬 Cancer doesn’t wait. Neither does Bicara Therapeutics. 👩⚕️ $BCAX’s mission as a clinical stage biotherapeutic company is clear: to turn groundbreaking discoveries into real, life-altering new cancer therapies. 🎉 Honored to be your exchange partner, congrats on becoming #NasdaqListed!
-
We are excited to share that we have closed our IPO and are listed on Nasdaq as BCAX! This marks an important new chapter for our company as we aim to deliver transformative bifunctional therapies to patients with solid tumors. Thank you to all of our dedicated team members and partners for the continued support in helping us achieve this milestone. https://lnkd.in/eNGgtmQx
-
We are delighted to announce the appointment of Mike Powell and Chris Bowden to our board of directors. Both individuals are esteemed leaders in the biopharma industry, and their extensive expertise will be instrumental as we progress ficerafusp alfa (BCA101) into its late-stage development for recurrent/metastatic head and neck squamous cell carcinoma, as well as other indications. For further details, visit: https://lnkd.in/gDmvcMPR
-
On July 27, we honor World Head and Neck Cancer Day to raise awareness and highlight the importance of knowing about these #cancers, along with effective care and control. Head and Neck Cancer is associated with a number of risk factors, many of which can be avoided and early detection is key to successful treatment. Be aware of the signs and symptoms, and if in doubt, get checked out! #WHNCD2024
-
Today, we are at the 3rd Hawaii Summit on Thoracic Malignancies, and excited to share updated interim data from our ongoing, open-label Phase 1/1b dose expansion study of ficerafusp alfa (BCA101) in 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma. #HNSCC is one of the most common cancers globally with a rising incidence, and this approach may become a new chemotherapy-free standard of care treatment for patients in need. Learn more in the release here: https://lnkd.in/e4PMdm6C
-
The two subtypes of Head and Neck Cancer (HNC) are distinctly associated with smoking/drinking and/or human papillomavirus (HPV) infection, and are often preventable. If diagnosed early, chances for survival can more than double. Screenings typically take less than 10 minutes. Get screened for HPV and HNC this #HeadandNeckCancerAwarenessMonth!